DCTH
Delcath Systems Inc
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Best Medical Devices Stocks 2026 →
Delcath Systems (DCTH) Stock: Buy, Sell, or Hold?
$20.10
-0.17 (-0.84%)
▼
5d:
+39.58%
30d:
+28.27%
90d:
+17.48%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (19%)
Quality Score
43/100
Position
EXTENDED
30-Day Fair Range
$13.76 – $16.66
Position: EXTENDED
Forward P/E & Valuation
167.5x
CHEAP
vs 200.1x historical avg
Wall Street Target
$26.60
+32.3% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$13.91 / $21.84
Trend: Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR BETTER ENTRY: DCTH is 20.6% above its trading range ($16.66). Market expects -5.8% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Get Alerted When DCTH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: DCTH is currently trading at $20.10, which is considered extended relative to its 30-day fair value range of $13.76 to $16.66. From a valuation perspective, the stock is trading at a discount (Forward PE: 167.5) compared to its historical average (200.1). Remarkably, the market is currently pricing in an annual earnings decline of 5.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, DCTH is in a uptrend. Immediate support is located at $13.91, while resistance sits at $21.84.
Market Sentiment: DCTH scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $26.60 (+32.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DCTH is in a uptrend. Immediate support is located at $13.91, while resistance sits at $21.84.
Market Sentiment: DCTH scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $26.60 (+32.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$13.76 -
$16.66
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
19.0%
Trading Range & Key Levels
30-Day Trading Range
$13.76 -
$16.66
Current vs Trading Range
EXTENDED
Support Level
$13.91
Resistance Level
$21.84
Current Trend
Uptrend
Technical data as of
Nov 10, 2026
Quantitative Signal Breakdown
- BEARISH: Price significantly overextended (+20.6% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 32.3% below Wall St target ($26.60)
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
167.50
Wall Street Target
$26.60
(+32.3%)
Revenue Growth (YoY)
20.6%
Profit Margin
0.6%
Valuation Discount vs History
-5.8% cheaper
PE vs Historical
167.5 vs 200.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.8%
(market-implied from PE analysis)
1-Year Target
$18.93
(-6%)
2-Year Target
$17.84
(-11%)
3-Year Target
$16.80
(-16%)
3-Yr Target (if PE normalizes)
(PE: 168→200)
$20.07
(0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 167.5 to 200.1
Stabilization Target:
$24.01
(+19.5%)
PE Expansion Potential:
+19.5%
Share DCTH Analysis
Share this live DCTH analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (DCTH)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 10, 2026
Daily AI digest
AI Retail Discussion Summary:
Delcath Systems (DCTH) reported a 71% increase in total revenue for Q3 2026, achieved positive operating cash flow, and raised full-year guidance due to strong patient starts and adoption of combination therapies.
Key Retail Themes:
Revenue growth and expansion plans
Positive earnings results
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 4:39 AM ET
Data refreshes hourly during market hours. Next update: 5:39 AM
Data refreshes hourly during market hours. Next update: 5:39 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DCTH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
EW
Edwards Lifesciences Corp |
STRONG BUY
30 analysts |
$112 | 42 HOLD |
|
BSX
Boston Scientific Corp |
BUY
31 analysts |
$50 | 53 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
28 analysts |
$119 | 37 SELL |
|
MDT
Medtronic PLC |
BUY
30 analysts |
$105 | 35 SELL |
|
PODD
Insulet Corporation |
BUY
26 analysts |
$178 | 43 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive DCTH Research Pages
